WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer receives FDA Fast Track designation for tafamidis for transthyretin cardiomyopathy 06 June 2017
FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen® / Procrit® across all indications 25 May 2017
Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy 11 May 2017
Pfizer unveils ATLAS®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries 21 April 2017
XELJANZ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis 27 March 2017
The Union for International Cancer Control and Pfizer announce next phase of global grants initiative supporting metastatic breast cancer patients 09 March 2017
Ronald E. Blaylock elected to Pfizer's Board of Directors 24 February 2017
Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases 10 February 2017
Pfizer reports fourth-quarter and full-year 2016 results 31 January 2017
Pfizer announces expansion of ASPIRE awards program for 2017 to include $5.5M in funding for breast and hematologic cancers 14 December 2016
IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery 02 December 2016
Pfizer's Prevenar 13® receives approval for use in infants and children in China 02 November 2016
Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection 19 October 2016
Pfizer decides remaining one company best positions company to maximize future value creation 26 September 2016
Pfizer launches new "Moodivator" app to help support, encourage and motivate people with depression 14 September 2016
Pfizer appoints chief scientific officer for neuroscience research 08 September 2016
Pfizer to acquire small molecule anti-infective business from AstraZeneca 24 August 2016
Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease 12 August 2016
Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc. 02 August 2016
Pfizer receives World Health Organization prequalification for multi-dose vial presentation of Prevenar 13® 19 July 2016
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.